This 2022 extension of the STEP 1 trial assessed the effects of discontinuing semaglutide 2.4 mg weekly in adults with obesity. After 68 weeks of treatment, participants had lost an average of 17.3% of their body weight. One year post-withdrawal, they regained approximately two-thirds of this weight loss, resulting in
This randomized controlled trial evaluated the efficacy of a very low-calorie diet (VLCD), behavior therapy (BT), and their combination in treating obesity. Seventy-six obese women were assigned to one of the three interventions. At the end of treatment, weight losses were 13.1 kg (VLCD), 13.0 kg (BT), and 16.8 kg
This large-scale retrospective cohort study analyzed data from 65,093 adults (aged 20–79 years, BMI ≥35 kg/m²) who underwent Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG), or adjustable gastric banding (AGB) between 2005 and 2015 across 41 U.S. health systems. RYGB resulted in the greatest total weight loss at 1, 3,
This 2013 study analyzed national trends in the use of prescription antiobesity medications in the U.S. from 1991 to 2011. Findings revealed that phentermine dominated prescriptions, accounting for 86.6% in 2011. Usage peaked in 1996 and declined following the withdrawal of fenfluramine and dexfenfluramine due to safety concerns. By 2011,
This 2005 systematic review by Tsai and Wadden assessed the efficacy and cost-effectiveness of major commercial and organized self-help weight loss programs in the U.S. The review included studies on programs such as Weight Watchers, Health Management Resources (HMR), Take Off Pounds Sensibly (TOPS), OPTIFAST, and eDiets.com. Findings indicated that
This 1977 double-blind, placebo-controlled trial evaluated the efficacy of HCG injections in treating obesity. Participants received either HCG or placebo injections while adhering to a low-calorie diet. The study found no significant differences between the HCG and placebo groups in terms of weight loss, hunger levels, mood changes, or localized
This 2015 randomized, double-blind, placebo-controlled crossover study investigated the effects of a single intranasal dose of oxytocin (24 IU) on caloric intake and metabolic parameters in 25 healthy fasting men. Participants received either oxytocin or placebo before selecting and consuming a breakfast meal. Results demonstrated that oxytocin administration led to
